Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News InflaRx NV IFRX

Healthcare Biotechnology
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a... see more

Current News (NDAQ:IFRX)

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

GlobeNewswire 9 days ago

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

GlobeNewswire December 30, 2025

InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904

GlobeNewswire December 11, 2025

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

GlobeNewswire November 10, 2025

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

GlobeNewswire November 7, 2025

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

GlobeNewswire October 21, 2025

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire September 12, 2025

InflaRx Announces Participation in September Investor Conferences

GlobeNewswire August 21, 2025

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 7, 2025
View More News ››

Opinion & Analysis (NDAQ:IFRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IFRX)

New COVID Studie Q 1/22

It should also be noted that our other study is now being continued. It would not be published properly yet. The continuation of this...
Sokratesaes86 - January 9, 2022

Ab very very BiG Market

Inflarx sepsis drug. Cost in the US alone. Values from then are now much higher. In 2011, sepsis topped the list of the most cost...
Sokratesaes86 - January 9, 2022

Inflarex Countdown to Party

Inflarex IFRX Germany course 3.80 Biopharma Further decision studies will be completed in the 1st half of 2022 including: Vilobelimab is...
Sokratesaes86 - January 9, 2022

ifrx --covid application

https://www.inflarx.de/Home/Investors/Press-Releases.html
securitynnmotn - July 21, 2020

ifrx

More specifically, Baker Bros. Advisors was the largest shareholder of InflaRx N.V. (NASDAQ:IFRX), with a stake worth $6.8 million...
securitynnmotn - June 26, 2020

ifrx will be the next ino

from $3 to $34 in 6 months
securitynnmotn - June 25, 2020
View more Bullboard ››

Mullen Group Ltd

Mullen Group Ltd

Mullen Group Ltd. provides a range of trucking and logistics services in Canada and the United States. It operates through ...
View More »

Podcasts